Story perspectives

Johnson & Johnson Beats Earnings Expectations, Boosts Revenue Guidance

7/16/2025

45 4

Summary

Story summary

Johnson & Johnson (JNJ) reported Q2 2025 earnings with adjusted EPS of $2.77, surpassing expectations of $2.66.
Revenue increased 5.8% year-over-year to $23.74 billion, exceeding forecasts of $22.8 billion.
The company raised its full-year revenue guidance to $93.2-$93.6 billion and EPS to $10.80-$10.90.
Growth is driven by strong performance in MedTech and Innovative Medicine, despite challenges from legacy products.
JNJ's stock rose over 2% in premarket trading, indicating strong investor confidence.

History

Historical Context

Johnson & Johnson's involvement in the opioid crisis began in 2018, leading to over 500 lawsuits by 2019. In 2022, the company agreed to a $26 billion settlement, prompting a strategic shift towards MedTech and Innovative Medicine. By Q2 2025, this focus resulted in a 5.8% revenue increase, reflecting the healthcare sector's trend towards innovation amid regulatory challenges.

1 of 2

Story summary

Johnson & Johnson (JNJ) reported Q2 2025 earnings with adjusted EPS of $2.77, surpassing expectations of $2.66.
Revenue increased 5.8% year-over-year to $23.74 billion, exceeding forecasts of $22.8 billion.
The company raised its full-year revenue guidance to $93.2-$93.6 billion and EPS to $10.80-$10.90.
Growth is driven by strong performance in MedTech and Innovative Medicine, despite challenges from legacy products.
JNJ's stock rose over 2% in premarket trading, indicating strong investor confidence.

1 / 2